News articles about G1 Therapeutics (NASDAQ:GTHX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0304203369385 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
G1 Therapeutics (NASDAQ:GTHX) traded down $0.04 during trading hours on Thursday, reaching $19.41. The company had a trading volume of 32,100 shares, compared to its average volume of 112,114. The company has a market cap of $550.47 and a P/E ratio of -9.03. G1 Therapeutics has a one year low of $12.04 and a one year high of $28.67.
A number of analysts have recently issued reports on GTHX shares. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, BTIG Research started coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.40.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
What are top analysts saying about G1 Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for G1 Therapeutics and related companies.